Konica Minolta and Innovation Network Corporation of Japan Close Acquisition of Ambry Genetics

20-Oct-2017 Intellasia | BusinessWire | 2:04 AM Print This Post

TOKYO–(BUSINESS WIRE)–Konica Minolta, Inc. (“Konica Minolta”) (TOKYO: 4902) (ISIN:
JP3300600008) and Innovation Network Corporation of Japan (“INCJ”) today
announced the close of their joint acquisition of Ambry Genetics
Corporation (“Ambry”) on October 19, 2017 (JST). Known as a pioneer and
thought leader in genetic testing, Ambry is the first laboratory in the
world to offer hereditary cancer panels and clinical exome sequencing.


This strategic acquisition was announced on July 6, 2017. Through this
acquisition, Konica Minolta and INCJ will accelerate the precision
medicine business by creating a new medical platform to improve
patients’ quality of life while also saving the healthcare system money.

Ambry chose to partner with Konica Minolta to accelerate the development
of new diagnostic tests for many different diseases for patients
throughout the world. Together they have the combined resources,
technology, and scale to advance biomedical research on a global scale,
resulting in better tests for doctors and more precise treatments for
their patients.

About Konica Minolta

Konica Minolta, Inc. (Konica Minolta) is a global digital technology
company with core strengths in imaging and data analysis, optics,
materials, and nano-fabrication. Through innovation, we create products
and digital solutions for the betterment of business and society—today
and for generations to come. Across our Business Technologies,
Healthcare, and Industrial-facing businesses, we aspire to be an
Integral Value Provider that applies the full range of our company’s
expertise to offer comprehensive solutions to our customer’s most
pressing problems, work with our partners to ensure our solutions are
sustainable, anticipate and address tomorrow’s issues, and tailor each
solution to meet the unique and specific needs of our valued customers.
Leveraging these capabilities, Konica Minolta contributes to
productivity improvement and workflow change for our customers, and
provides leading-edge service solutions in the IoT era.

Headquartered in Tokyo and with operations in more than 50 countries,
Konica Minolta has more than 43,000 employees serving approximately two
million customers in over 150 countries. Konica Minolta is listed on the
Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/.

About INCJ

INCJ was established in July 2009 as a public-private investment company
that provides financial, technological and management support for
next-generation businesses. INCJ specifically supports those projects
that combine technologies and varied expertise across industries and
materialize open innovation. INCJ has the capacity to invest up to JPY2
trillion (approx. US$20 billion).

INCJ’s management team is drawn from the private sector with diverse
experience in investment, technologies and management. Through its
Innovation Network Committee, INCJ assesses investment opportunities
that contribute to industrial innovation in Japan in line with criteria
set by the government. For more information please see: http://www.incj.co.jp/english/.

About Ambry Genetics

Since 1999, Ambry’s mission has remained focused on understanding
disease so cures can come faster. Today, Ambry remains unwavering in its
commitment to being tough, innovative, committed to quality and, most of
all, focused to do what is right for patient care. For more information
on Ambry’s full suite of genetic testing, visit http://www.ambrygen.com.

Contacts

Konica Minolta
Konica Minolta Inc., Corporate Communications
Dept.
press@konicaminolta.com
+81-3-6250-2100
or
Innovation
Network Corporation of Japan

INCJ Group PR:
Irie, Sakai
+81-3-5218-7202

 


Category: BusinessWire, PRAsia

Print This Post